The present disclosure is drawn to an endolysin
protein against
Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal
bacteria, said diseases including but not limited to pneumonia, invasive
pneumococcal disease,
meningitis and
sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (
RNA /
DNA) or variants thereof.